근이완제 시장 보고서(2026년)

Muscle relaxant drugs are medications that help relieve muscle tension and spasms. They are commonly prescribed to treat conditions such as muscle injuries, back pain, and neurological disorders.

The main types of muscle relaxant drugs include facial muscle relaxants, skeletal muscle relaxants, and neuromuscular blocking agents. Facial muscle relaxants are used to treat facial spasms and cramps. The routes of administration for muscle relaxants include oral, injectable, spray, and ointment, with various formulations such as cyclobenzaprine, carisoprodol, chlorzoxazone, metaxalone, methocarbamol, baclofen, tizanidine, orphenadrine, and dantrolene. These drugs are used by hospitals, home care settings, specialty clinics, and other healthcare providers.

Tariffs have influenced the muscle relaxant drugs market by increasing import costs for raw materials and active pharmaceutical ingredients, particularly impacting injectable and specialty formulations. Asia-Pacific regions, including india and china, face higher production costs, slowing supply chains. Hospitals and specialty clinics are most affected by these cost shifts. However, tariffs are encouraging local manufacturing investments and the development of cost-efficient drug alternatives, which could strengthen domestic production capabilities and reduce long-term dependency on imports.

The muscle relaxant drugs market research report is one of a series of new reports from The Business Research Company that provides muscle relaxant drugs market statistics, including muscle relaxant drugs industry global market size, regional shares, competitors with a muscle relaxant drugs market share, detailed muscle relaxant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the muscle relaxant drugs industry. This muscle relaxant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle relaxant drugs market size has grown strongly in recent years. It will grow from $5.11 billion in 2025 to $5.51 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growing prevalence of musculoskeletal disorders, rising cases of back pain and muscle injuries, increased hospital visits for neurological disorders, expansion of hospital infrastructure, advancements in oral and injectable formulations.

The muscle relaxant drugs market size is expected to see strong growth in the next few years. It will grow to $7.43 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing homecare and telemedicine adoption, increasing personalized medicine and precision therapy, rising geriatric population, innovations in targeted neuromuscular drugs, expansion of emerging markets in asia-pacific and latin america. Major trends in the forecast period include increasing adoption of non-opioid muscle relaxants, rising demand for personalized therapy in muscle disorders, growth in homecare muscle relaxation treatments, expansion of injectable and topical formulations, increasing awareness of musculoskeletal health.

The growing number of sports injuries is expected to drive the growth of the muscle relaxant drugs market. Sports injuries encompass a wide range of physical injuries resulting from participation in athletic activities, affecting various parts of the body, including muscles, bones, tendons, ligaments, and joints. Muscle relaxants are often used to treat muscle spasms and injuries by influencing the central nervous system to alleviate muscle tension and promote relaxation. For example, in 2024, Injury Facts, a report by the National Safety Council (NSC), a U.S.-based public health and safety organization, indicated that emergency department visits for sports and recreational equipment injuries increased by 12% in 2022, rose another 2% in 2023, and surged by 17% in 2024, reaching an estimated 4.4 million people treated in 2024. As a result, the rise in sports injuries is expected to contribute to the growth of the muscle relaxant drugs market.

Major companies in the muscle relaxant drug market are focusing on developing innovative products, such as generic muscle relaxant injectables, to gain a competitive edge and enhance cost efficiency. Generic muscle relaxant injectables are affordable, non-branded medications that are administered through injection and contain the same active ingredients as their branded counterparts. For example, in November 2023, Lupin Limited, an India-based pharmaceutical company, launched Rocuronium Bromide Injection in formulations of 50 mg/5 mL and 100 mg/10 mL multiple-dose vials. This launch followed the approval of the Abbreviated New Drug Application (ANDA) by Lupin's alliance partner, Caplin Steriles Limited, from the U.S. Food and Drug Administration (FDA). The newly introduced generic version serves as an alternative to Zemuron Injection by Organon USA Inc., offering skeletal muscle relaxation during surgery or mechanical ventilation. It is indicated for both inpatients and outpatients, acting as an adjunct to general anesthesia and facilitating rapid sequence and routine tracheal intubation.

In June 2023, Corona Remedies, an India-based pharmaceutical company, acquired the muscle relaxant brand Myoril from Sanofi India for INR 234 crore ($31 million). This strategic acquisition includes Myoril and its extensions, which have annual sales of INR 38 crore ($5 million) and a growth rate of 6.8%. The move is aimed at strengthening CORONA Remedies' position in the rapidly growing Indian muscle relaxant market, valued at INR 1,626 crore ($217 million). Sanofi India is a prominent healthcare and pharmaceutical company in India, specializing in muscle relaxant drugs.

Major companies operating in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma SA, Par Pharmaceutical Companies Inc., Novartis AG, Accord Healthcare Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Lannett Company Inc., Unichem Laboratories, Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd., Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the muscle relaxant drugs market share in 2025. The regions covered in the muscle relaxant drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle relaxant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The muscle relaxant drugs market consists of sales of antispasmodics, benzodiazepines and nonbenzodiazepines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Relaxant Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses muscle relaxant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle relaxant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The muscle relaxant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Facial Muscle Relaxant Drugs; Skeletal Muscle Relaxant Drugs; Neuromuscular Blocking Agents
• 2) By Formulation: Cyclobenzaprine; Carisoprodol; Chlorzoxazone; Metaxalone; Methocarbamol; Baclofen; Tizanidine; Orphenadrine; Dantrolene
• 3) By Route Of Administration: Oral; Injectable; Spray; Ointment
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Facial Muscle Relaxant Drugs: Botulinum Toxin; Dysport; Xeomin
• 2) By Skeletal Muscle Relaxant Drugs: Centrally Acting Muscle Relaxants; Peripherally Acting Muscle Relaxants
• 3) By Neuromuscular Blocking Agents: Non-Depolarizing Agents; Depolarizing Agents
• Companies Mentioned: Pfizer Inc.; Ipsen Pharma SA; Par Pharmaceutical Companies Inc.; Novartis AG; Accord Healthcare Ltd.; Amneal Pharmaceuticals LLC; Aurobindo Pharma Ltd.; Mylan NV; Hikma Pharmaceuticals PLC; Akorn Incorporated; Merck & Co. Inc.; Teva Pharmaceuticals Industries Ltd.; Dr. Reddy's Laboratories; Lannett Company Inc.; Unichem Laboratories; Endo Pharmaceuticals Inc.; Abbvie Inc.; Merz Pharmaceuticals LLC; Vertical Pharmaceuticals LLC; Mallinckrodt Pharmaceuticals; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Cadila Healthcare Ltd.; Torrent Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Glenmark Pharmaceuticals Ltd.; Cipla Ltd.; Lupin Ltd.; Intas Pharmaceuticals Ltd.; Alkem Laboratories Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Muscle Relaxant Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Muscle Relaxant Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Muscle Relaxant Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Muscle Relaxant Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Non-Opioid Muscle Relaxants
  • 4.2.2 Rising Demand For Personalized Therapy In Muscle Disorders
  • 4.2.3 Growth In Homecare Muscle Relaxation Treatments
  • 4.2.4 Expansion Of Injectable And Topical Formulations
  • 4.2.5 Increasing Awareness Of Musculoskeletal Health

5. Muscle Relaxant Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Homecare Providers
• 5.3 Specialty Clinics
• 5.4 Rehabilitation Centers
• 5.5 Physiotherapy Clinics

6. Muscle Relaxant Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Muscle Relaxant Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Muscle Relaxant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Muscle Relaxant Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Muscle Relaxant Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Muscle Relaxant Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Muscle Relaxant Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Muscle Relaxant Drugs Market Segmentation

• 9.1. Global Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Facial Muscle Relaxant Drugs, Skeletal Muscle Relaxant Drugs, Neuromuscular Blocking Agents
• 9.2. Global Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Cyclobenzaprine, Carisoprodol, Chlorzoxazone, Metaxalone, Methocarbamol, Baclofen, Tizanidine, Orphenadrine, Dantrolene
• 9.3. Global Muscle Relaxant Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Spray, Ointment
• 9.4. Global Muscle Relaxant Drugs Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End-Users
• 9.5. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Facial Muscle Relaxant Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Botulinum Toxin, Dysport, Xeomin
• 9.6. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Skeletal Muscle Relaxant Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Centrally Acting Muscle Relaxants, Peripherally Acting Muscle Relaxants
• 9.7. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Neuromuscular Blocking Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Non-Depolarizing Agents, Depolarizing Agents

10. Muscle Relaxant Drugs Market Regional And Country Analysis

• 10.1. Global Muscle Relaxant Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Muscle Relaxant Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Muscle Relaxant Drugs Market

• 11.1. Asia-Pacific Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Muscle Relaxant Drugs Market

• 12.1. China Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Muscle Relaxant Drugs Market

• 13.1. India Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Muscle Relaxant Drugs Market

• 14.1. Japan Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Muscle Relaxant Drugs Market

• 15.1. Australia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Muscle Relaxant Drugs Market

• 16.1. Indonesia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Muscle Relaxant Drugs Market

• 17.1. South Korea Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Muscle Relaxant Drugs Market

• 18.1. Taiwan Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Muscle Relaxant Drugs Market

• 19.1. South East Asia Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Muscle Relaxant Drugs Market

• 20.1. Western Europe Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Muscle Relaxant Drugs Market

• 21.1. UK Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Muscle Relaxant Drugs Market

• 22.1. Germany Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Muscle Relaxant Drugs Market

• 23.1. France Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Muscle Relaxant Drugs Market

• 24.1. Italy Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Muscle Relaxant Drugs Market

• 25.1. Spain Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Muscle Relaxant Drugs Market

• 26.1. Eastern Europe Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Muscle Relaxant Drugs Market

• 27.1. Russia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Muscle Relaxant Drugs Market

• 28.1. North America Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Muscle Relaxant Drugs Market

• 29.1. USA Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Muscle Relaxant Drugs Market

• 30.1. Canada Muscle Relaxant Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Muscle Relaxant Drugs Market

• 31.1. South America Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Muscle Relaxant Drugs Market

• 32.1. Brazil Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Muscle Relaxant Drugs Market

• 33.1. Middle East Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Muscle Relaxant Drugs Market

• 34.1. Africa Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Muscle Relaxant Drugs Market, Segmentation By Drug Type, Segmentation By Formulation, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Muscle Relaxant Drugs Market Regulatory and Investment Landscape

36. Muscle Relaxant Drugs Market Competitive Landscape And Company Profiles

• 36.1. Muscle Relaxant Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Muscle Relaxant Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Muscle Relaxant Drugs Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Ipsen Pharma SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Par Pharmaceutical Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Accord Healthcare Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Muscle Relaxant Drugs Market Other Major And Innovative Companies

• Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Dr. Reddy's Laboratories, Lannett Company Inc., Unichem Laboratories, Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals

38. Global Muscle Relaxant Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Muscle Relaxant Drugs Market

40. Muscle Relaxant Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Muscle Relaxant Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Muscle Relaxant Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Muscle Relaxant Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer